Cargando…
CDK9 inhibitors in multiple myeloma: a review of progress and perspectives
Currently, multiple myeloma is not yet considered a curable disease. Despite the recent advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 inhibitors emerged as a suitable agent to overcome resistance and prolong survival in patients with poor diagnoses. Downre...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800928/ https://www.ncbi.nlm.nih.gov/pubmed/35092513 http://dx.doi.org/10.1007/s12032-021-01636-1 |